Technology
CSIR-CCMB sickle cell score matches doctors in 85%
The Hindu··2 Oct
CSIR-CCMB scientists built India-specific sickle cell severity scores using records of 171 children treated in Nagpur. The international Paediatric Severity Score matched expert assessments in about 67 percent of cases. Revised models ISS1 and ISS2 raised concordance to nearly 83 percent and about 85 percent. Giriraj R. Chandak said the tools could guide hydroxyurea use after wider validation.
Prism
What It Means For You
- Doctors treating Indian sickle cell patients may gain a local severity score instead of foreign-only models.
- ISS2 uses observable clinical signs so some decisions need fewer lab tests.
- Researchers say larger validation is still required before wide adoption.
What's Happening
- Two paediatricians independently classed the 171 Nagpur children as mild, moderate or severe.
- ISS1 added features such as recurrent transfusions, severe anaemia and acute febrile illnesses.
- Painful vaso-occlusive crises were the most common complication in the study group.
Why India Needed Its Own Score
- Indian patients often show a milder profile than many African cohorts, partly from higher foetal haemoglobin.
- Complications common elsewhere, such as leg ulcers and pulmonary hypertension, are rarer here.
- Nutritional gaps and infections can still worsen anaemia in Indian settings.
all-news
